Dr. Brandon R. Weckbaugh
Claim this profileCotton O'Neil Cancer Center / Stormont Vail Health
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
16 drugs studied
Area of expertise
1Lung Cancer
Stage III
Stage II
Stage I
2Non-Small Cell Lung Cancer
Stage III
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Brandon R. Weckbaugh is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
More about Brandon R. Weckbaugh
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Brandon R. Weckbaugh has experience with
- Biospecimen Collection
- Azacitidine
- Venetoclax
- Text-Based Cessation Intervention
- Atezolizumab
- Cabozantinib S-malate
Breakdown of trials Brandon R. Weckbaugh has run
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brandon R. Weckbaugh specialize in?
Brandon R. Weckbaugh focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Brandon R. Weckbaugh currently recruiting for clinical trials?
Yes, Brandon R. Weckbaugh is currently recruiting for 6 clinical trials in Topeka Kansas. If you're interested in participating, you should apply.
Are there any treatments that Brandon R. Weckbaugh has studied deeply?
Yes, Brandon R. Weckbaugh has studied treatments such as Biospecimen Collection, Azacitidine, Venetoclax.
What is the best way to schedule an appointment with Brandon R. Weckbaugh?
Apply for one of the trials that Brandon R. Weckbaugh is conducting.
What is the office address of Brandon R. Weckbaugh?
The office of Brandon R. Weckbaugh is located at: Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas 66606 United States. This is the address for their practice at the Cotton O'Neil Cancer Center / Stormont Vail Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.